Status:
COMPLETED
Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
Lead Sponsor:
Kumamoto University
Collaborating Sponsors:
The 4C trial bureau
Japan Heart Foundation
Conditions:
Hypertension
Coronary Artery Disease
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting st...
Detailed Description
It was reported that low-dose angiotensin II receptor blocker, candesartan, was effective to prevent cardiovascular events in patients with coronary artery disease treated with coronary angioplasty (A...
Eligibility Criteria
Inclusion
- A. Patients with hypertension, systolic blood pressure (SBP) = or \> 140 and/or diastolic blood pressure (DBP) = or \> 90
- B. Patients with symptomatic heart failure lasting at least for 4 weeks (NYHA class = or \> II), or those need continuous use of diuretics
- C. Patients underwent coronary angioplasty with drug-eluting stents
- Eligible patients are those who meet (A or B) and C.
Exclusion
- Severe renal or hepatic disease
- Candidates for coronary artery bypass grafting (CABG)
- Within 3 months after CABG
- Allergic history to candesartan
- Pregnant women
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
1119 Patients enrolled
Trial Details
Trial ID
NCT00139386
Start Date
October 1 2005
End Date
April 1 2012
Last Update
April 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
Kumamoto, Japan, 860-8556